Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)

Hasan I.; Murti I.S.; Bayupurnama P.; Kalista K.F.; Hill-Zabala C.; Kananda D.; Viayna E.
Hasan, Irsan (12776850800); Murti, Ignatia Sinta (57210325442); Bayupurnama, Putut (20733356900); Kalista, Kemal Fariz (57200425631); Hill-Zabala, Christina (9939010500); Kananda, Dennis (59125988400); Viayna, Elisabet (24400267100)
12776850800; 57210325442; 20733356900; 57200425631; 9939010500; 59125988400; 24400267100
Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings
2024
Drugs in Context
13
0
Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Department of Internal Medicine, Abdul Wahab Sjahranie General Hospital Samarinda, East Kalimantan, Indonesia; Gastroenterology & Hepatology Division, Department of Internal Medicine, Dr. Sardjito General Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Grifols Asia Pacific Pte Ltd, Singapore; IQVIA, Jakarta, Indonesia; Grifols SA, Sant Cugat del Vallès, Spain
Hasan I., Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Murti I.S., Department of Internal Medicine, Abdul Wahab Sjahranie General Hospital Samarinda, East Kalimantan, Indonesia; Bayupurnama P., Gastroenterology & Hepatology Division, Department of Internal Medicine, Dr. Sardjito General Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Kalista K.F., Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Hill-Zabala C., Grifols Asia Pacific Pte Ltd, Singapore; Kananda D., IQVIA, Jakarta, Indonesia; Viayna E., Grifols SA, Sant Cugat del Vallès, Spain
Background: Human albumin (HA) is an effective ad-juvant treatment for patients with cirrhosis developing spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS) and ascites requiring large-volume paracentesis (LVP). However, cost remains a barrier to use, particularly in resource-limited settings. This study aims to assess the cost-effectiveness of HA in patients with cirrhosis with SBP, HRS or ascites requiring LVP in the Indonesian healthcare system as a representative of a resource-limited setting. Methods: Three decision-tree models were developed to assess the cost-effectiveness of (1) antibiotics and HA versus antibiotics alone in patients with SBP, (2) terlipressin and HA versus terlipressin alone in patients with HRS, and (3) LVP and HA versus LVP and gelatine for patients with ascites. Clinical utility and economic inputs were pooled from the available literature. Time horizon was 3 months. Outcomes were expressed as incremental cost-effectiveness ratios (ICER) reported as 2021 IDR per quality-adjusted life year (QALY) (exchange rate June 30, 2021: 1 EUR = 17,245 IDR). Willingness-to-pay thresholds considered were: three times the GDP per capita (199,355,561 IDR/QALY; 11,560 EUR/QALY) and one time the GDP per capita (66,451,854 IDR/QALY; 3853 EUR/QALY). Results: The ICER for antibiotics and HA (versus antibiotics alone) for SBP was 80,562,652 IDR per QALY gained (4672 EUR/QALY). The ICER for terlipressin and HA (versus terlipressin) for HRS was 23,085,004 IDR per QALY gained (1339 EUR/QALY). The ICER for LVP and HA versus LVP and gelatine was 24,569,827 IDR per QALY gained (1425 EUR/QALY). Conclusion: Adjunctive HA may be a cost-effective treatment for SBP, HRS and LVP in resource-limited settings. © 2024 Hasan I, Murti IS, Bayupurnama P, Kalista KF, Hill-Zabala C, Kananda D, Viayna E. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
cost-effectiveness; human albumin; Indonesia; liver cirrhosis; liver diseases; resource-limited settings
cefotaxime; gelatin; human albumin; terlipressin; Article; ascites; bacterial peritonitis; cost effectiveness analysis; decision tree; decompensated liver cirrhosis; drug cost; drug megadose; economic evaluation; economic model; female; health care system; health care utilization; health economics; hepatic encephalopathy; hepatorenal syndrome; hospitalization; human; hyponatremia; kidney dysfunction; male; monotherapy; paracentesis; quality adjusted life year; survival analysis; treatment duration; Willingness To Pay
Xcenda LLC; Grifols Asia Pacific Pte Ltd
Jordi Bozzo PhD, CMPP (Grifols) is acknowledged for assistance in the preparation of the manuscript. M Chris Runken from Grifols SSNA and Rashad Carlton from Xcenda LLC are acknowledged for their support in the original model development and interpretation. Royasia Ramadani is acknowledged for her support in the literature review and interpretation of results. Prof. Rino Alvani Gani MD, PhD, Prof.
Bioexcel Publishing LTD
17451981
Article
Q2
845
5506